Menu
Search
|

Menu

Close
X

Bioblast Pharma Ltd ORPN.OQ (NASDAQ Stock Exchange Capital Market)

1.54 USD
+0.04 (+2.67%)
As of Jul 20
chart
Previous Close 1.50
Open 1.49
Volume 3,333
3m Avg Volume 19,053
Today’s High 1.57
Today’s Low 1.49
52 Week High 5.99
52 Week Low 1.44
Shares Outstanding (mil) 3.34
Market Capitalization (mil) 7.39
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
FY15
0
EPS (USD)
FY17
-1.802
FY16
-5.075
FY15
-5.399
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
--
5.73
Price to Book (MRQ)
vs sector
1.56
5.47
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
0.00
16.84
LT Debt to Equity (MRQ)
vs sector
0.00
12.51
Return on Investment (TTM)
vs sector
-119.23
14.61
Return on Equity (TTM)
vs sector
-119.23
16.34

EXECUTIVE LEADERSHIP

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

15th Floor, 37 Dereh Menachem Be
TEL AVIV-YAFO     6522042

Phone: +9723.7326616

Bioblast Pharma Ltd (BioBlast) is an Israel-based development-stage biopharmaceutical company. The Company is focused on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic and metabolic diseases. It focuses on therapeutic platforms that offer solutions for several diseases that share a common pathophysiological mechanism, which are the functional changes that accompany a particular syndrome or disease. It also focuses on diseases with severe and debilitating manifestations. The Company has several drug candidates in clinical or preclinical development targeting neuromuscular/central nervous system (CNS) and mitochondrial diseases. Its drug candidates include Trehalose IV Solution, BB-FA (Bioblast-Friedreich's ataxia) and BBrm-02. The Company's product candidate platforms include Protein Stabilizing Platform, Read-through Platform and Mitochondrial Protein Replacement Platform.

SPONSORED STORIES